Provided by Tiger Trade Technology Pte. Ltd.

Adial Pharmaceuticals

6.22
+0.31505.34%
Post-market: 6.03-0.1850-2.98%19:30 EDT
Volume:81.99K
Turnover:493.98K
Market Cap:16.32M
PE:-0.35
High:6.41
Open:5.95
Low:5.74
Close:5.90
52wk High:10.75
52wk Low:1.31
Shares:2.63M
Float Shares:2.55M
Volume Ratio:0.92
T/O Rate:3.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.7100
EPS(LYR):-11.9306
ROE:-2011.66%
ROA:-40.08%
PB:-0.43
PE(LYR):-0.52

Loading ...

Company Profile

Company Name:
Adial Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
5
Office Location:
4870 Sadler Road,Suite 300,Glen Allen,Virginia,United States
Zip Code:
23060
Fax:
- -
Introduction:
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

Directors

Name
Position
Cary J. Claiborne
Chief Executive Officer, President and Director
Kevin Schuyler
Chairman of the Board and Lead Independent Director
Tony Goodman
Chief Operating Officer and Director
J. Kermit Anderson
Director
Robertson H. Gilliland
Director

Shareholders

Name
Position
Cary J. Claiborne
Chief Executive Officer, President and Director
Tony Goodman
Chief Operating Officer and Director
Vinay Shah
Chief Financial Officer